Christopher Compton, MD
Family Medicine · Cape Girardeau, MONPI 1174567176
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,235 of the $17,921 with a category attached, or 62.7%. 52 manufacturers reported payments, led by Tactile Systems Technology Inc at 37.3% of the total. Reporting peaked in 2024 at $8,901 and has fallen 91.4% since, to $769 in 2025. Among family medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 729 payments — averaging $24.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tactile Systems Technology Inc$7K
- AbbVie$4K
- Lilly USA, LLC$918
- Novo Nordisk$617
- Astellas Pharma US Inc$467
- Pfizer$450
- plus $5K from 46 others
What the payments were for
- Speaking & faculty fees$6,40036%
- Travel & lodging$2862%
- Food & beverage$11,23563%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Flexitouch Plus$6,686
- Entre Plus$6,686
How this compares
$17,921 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 120 | $81,923 |
| XareltoRivaroxaban | 75 | $72,160 |
| JardianceEmpagliflozin | 41 | $42,609 |
| OzempicSemaglutide | 22 | $38,890 |
| MounjaroTirzepatide | 33 | $38,525 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $29,869 |
| JanuviaSitagliptin Phosphate | 27 | $22,223 |
| TrulicityDulaglutide | 13 | $20,448 |
| FarxigaDapagliflozin Propanediol | 17 | $16,758 |
| MyrbetriqMirabegron | 25 | $15,592 |
| Spiriva HandihalerTiotropium Bromide | 16 | $10,045 |
| OxycontinOxycodone Hcl | 13 | $9,275 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $8,650 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $8,060 |
| GemtesaVibegron | 12 | $7,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Prempro | $450 | $85,782131 claims |
| Johnson & JohnsonXarelto | $334 | $72,16075 claims |
| Lilly USA, LLCMounjaro, Trulicity | $918 | $58,97346 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy | $298 | $43,56973 claims |
| Boehringer IngelheimJardiance | $425 | $42,60941 claims |
| Novo NordiskOzempic | $617 | $38,89022 claims |
| MerckJanuvia, Steglatro | $141 | $25,89938 claims |
| AstraZenecaFarxiga, Symbicort | $444 | $22,15432 claims |
| Astellas Pharma US IncMyrbetriq | $467 | $15,59225 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $237 | $7,39212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $49 | $5,73612 claims |
| AbbVieSynthroid | $3,641 | $3,77966 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Cape Girardeau
- Lori MoyersCape Girardeau$21K
- Robert BieserCape Girardeau$16K
- Shahzaib AnwarCape Girardeau$14K
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.